-
Signature
-
venBio Global Strategic Fund III, L.P., by: venBio Global Strategic GP III, L.P., its general partner, by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact
-
Stock symbol
-
RYZB
-
Transactions as of
-
Sep 19, 2023
-
Transactions value $
-
$0
-
Form type
-
4
-
Date filed
-
9/21/2023, 04:30 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
RYZB |
Common Stock |
Conversion of derivative security |
|
+3.79M |
|
|
3.79M |
Sep 19, 2023 |
Direct |
F1, F4 |
transaction |
RYZB |
Common Stock |
Conversion of derivative security |
|
+1.12M |
+29.68% |
|
4.91M |
Sep 19, 2023 |
Direct |
F2, F4 |
transaction |
RYZB |
Common Stock |
Conversion of derivative security |
|
+247K |
+5.04% |
|
5.16M |
Sep 19, 2023 |
Direct |
F3, F4 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
RYZB |
Series A Convertible Preferred Stock |
Conversion of derivative security |
|
-3.79M |
-100% |
|
0 |
Sep 19, 2023 |
Common Stock |
3.79M |
|
Direct |
F1, F4 |
transaction |
RYZB |
Series B Convertible Preferred Stock |
Conversion of derivative security |
|
-1.12M |
-100% |
|
0 |
Sep 19, 2023 |
Common Stock |
1.12M |
|
Direct |
F2, F4 |
transaction |
RYZB |
Series C Convertible Preferred Stock |
Conversion of derivative security |
|
-216K |
-100% |
|
0 |
Sep 19, 2023 |
Common Stock |
247K |
|
Direct |
F3, F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
venBio Global Strategic Fund III, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses:
Remarks:
Dr. Aaron Royston serves as a member of the Issuer's board of directors and is a director of venBio Ltd. However, Dr. Royston disclaims beneficial ownership over the securities held by venBio III.